Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.
1 report, 1 independent
Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Europe
terrestrial continent located in north-western Eurasia